Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Apr 04, 2023 4:18pm
222 Views
Post# 35379586

RE:RE:RE:Example of a jv deal

RE:RE:RE:Example of a jv deal

Eoganacht wrote: Conferences are more about educating urologists as to the advantages of our treatment, so that when we are allowed to commercialize there is a ( hopefully eagerly anticipating ) market for our product.  Despite all the cynical conspiracy theories being noised about, I believe medical specialists are genuinely looking out for the best interests of their patients - and that entails providing them with the best possible treatment. And if urologists understand that TLD1433 PDT is the best treatment available for BCG unresponsive NMIBC this will translate into having the lion's share of this market and a very healthy stock price.

 

The practice of medicine (under the pressure of high costs & a growing centralized/managed healthcare system) is becoming more & more evidence-based (i.e. less bending to individual physician preferences), & drug formulary committees have to not only consider a drug or treatment's efficacy & safety, but also have to examine the impact of cost/reimbursement potential in this high cost environment. The above trend should favor our ACT.  Drug/supply chain shortages (I.e. BCG) should also lend support for use of our ACT.  

If all continues to go well from a data/scientific perspective, getting physician leaders to buy-in to our ACT should be a relatively small hill to climb....just need to continue to get the word out.  All imo.

<< Previous
Bullboard Posts
Next >>